Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.13
DVA's Cash-to-Debt is ranked lower than
67% of the 243 Companies
in the Global Medical Care industry.

( Industry Median: 0.34 vs. DVA: 0.13 )
Ranked among companies with meaningful Cash-to-Debt only.
DVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.11 Max: 3.35
Current: 0.13
0.01
3.35
Equity-to-Asset 0.25
DVA's Equity-to-Asset is ranked lower than
81% of the 241 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. DVA: 0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
DVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.24 Max: 0.34
Current: 0.25
0.04
0.34
Interest Coverage 4.57
DVA's Interest Coverage is ranked lower than
70% of the 218 Companies
in the Global Medical Care industry.

( Industry Median: 7.64 vs. DVA: 4.57 )
Ranked among companies with meaningful Interest Coverage only.
DVA' s Interest Coverage Range Over the Past 10 Years
Min: 2.87  Med: 4.46 Max: 5.47
Current: 4.57
2.87
5.47
Piotroski F-Score: 7
Altman Z-Score: 2.05
Beneish M-Score: -2.64
WACC vs ROIC
7.27%
10.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 12.85
DVA's Operating Margin % is ranked higher than
65% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 7.23 vs. DVA: 12.85 )
Ranked among companies with meaningful Operating Margin % only.
DVA' s Operating Margin % Range Over the Past 10 Years
Min: 8.49  Med: 15.37 Max: 17.15
Current: 12.85
8.49
17.15
Net Margin % 5.97
DVA's Net Margin % is ranked higher than
57% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 4.95 vs. DVA: 5.97 )
Ranked among companies with meaningful Net Margin % only.
DVA' s Net Margin % Range Over the Past 10 Years
Min: 1.96  Med: 6.54 Max: 7.25
Current: 5.97
1.96
7.25
ROE % 18.42
DVA's ROE % is ranked higher than
75% of the 229 Companies
in the Global Medical Care industry.

( Industry Median: 10.69 vs. DVA: 18.42 )
Ranked among companies with meaningful ROE % only.
DVA' s ROE % Range Over the Past 10 Years
Min: 5.37  Med: 19.11 Max: 25.64
Current: 18.42
5.37
25.64
ROA % 4.71
DVA's ROA % is ranked higher than
51% of the 246 Companies
in the Global Medical Care industry.

( Industry Median: 4.67 vs. DVA: 4.71 )
Ranked among companies with meaningful ROA % only.
DVA' s ROA % Range Over the Past 10 Years
Min: 1.49  Med: 4.95 Max: 5.69
Current: 4.71
1.49
5.69
ROC (Joel Greenblatt) % 57.96
DVA's ROC (Joel Greenblatt) % is ranked higher than
79% of the 246 Companies
in the Global Medical Care industry.

( Industry Median: 21.13 vs. DVA: 57.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 38.04  Med: 56.82 Max: 68.47
Current: 57.96
38.04
68.47
3-Year Revenue Growth Rate 9.50
DVA's 3-Year Revenue Growth Rate is ranked higher than
59% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. DVA: 9.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.8  Med: 12.5 Max: 39.8
Current: 9.5
4.8
39.8
3-Year EBITDA Growth Rate 9.70
DVA's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 152 Companies
in the Global Medical Care industry.

( Industry Median: 6.70 vs. DVA: 9.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -0.6  Med: 15 Max: 98.2
Current: 9.7
-0.6
98.2
3-Year EPS without NRI Growth Rate 14.10
DVA's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: 6.80 vs. DVA: 14.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29  Med: 14.1 Max: 125.5
Current: 14.1
-29
125.5
GuruFocus has detected 2 Warning Signs with DaVita Inc $DVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DVA Guru Trades in Q1 2016

Andreas Halvorsen 1,744,519 sh (New)
Joel Greenblatt 513,100 sh (+69.62%)
Arnold Van Den Berg 328,908 sh (+22.67%)
Jim Simons 1,091,500 sh (+18.11%)
Mario Gabelli 41,563 sh (+4.00%)
Manning & Napier Advisors, Inc 1,911,305 sh (+1.27%)
Warren Buffett 38,565,570 sh (unchged)
Alan Fournier Sold Out
Paul Tudor Jones Sold Out
Ray Dalio 6,600 sh (-79.34%)
» More
Q2 2016

DVA Guru Trades in Q2 2016

Ray Dalio 75,970 sh (+1051.06%)
Andreas Halvorsen 4,611,729 sh (+164.36%)
Jim Simons 1,376,800 sh (+26.14%)
Warren Buffett 38,565,570 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 40,363 sh (-2.89%)
Manning & Napier Advisors, Inc 1,375,595 sh (-28.03%)
Arnold Van Den Berg 79,300 sh (-75.89%)
» More
Q3 2016

DVA Guru Trades in Q3 2016

Joel Greenblatt 45,595 sh (New)
Warren Buffett 38,565,570 sh (unchged)
Andreas Halvorsen Sold Out
Manning & Napier Advisors, Inc 1,354,745 sh (-1.52%)
Arnold Van Den Berg 77,285 sh (-2.54%)
Jim Simons 1,313,500 sh (-4.60%)
Ray Dalio 65,300 sh (-14.05%)
Mario Gabelli 32,613 sh (-19.20%)
» More
Q4 2016

DVA Guru Trades in Q4 2016

Steven Cohen 283,200 sh (New)
Richard Pzena 3,327 sh (New)
Joel Greenblatt 440,617 sh (+866.37%)
Ray Dalio 88,244 sh (+35.14%)
Warren Buffett 38,565,570 sh (unchged)
Arnold Van Den Berg Sold Out
Mario Gabelli 21,663 sh (-33.58%)
Jim Simons 844,500 sh (-35.71%)
Manning & Napier Advisors, Inc 288,580 sh (-78.70%)
» More
» Details

Insider Trades

Latest Guru Trades with DVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621492    SIC: 8092
Compare:NYSE:UHS, OTCPK:RMSYF, NYSE:EVHC, NAS:WOOF, OTCPK:SKHCY, NYSE:MD, OTCPK:CAKFY, OTCPK:NMHLY, NYSE:HLS, NAS:ACHC, NYSE:CHE, OTCPK:LTGHY, NAS:LPNT, NAS:SCAI, NYSE:AMN, NYSE:THC, NYSE:SEM, NAS:AMED, NYSE:FMS, NAS:PAHC » details
Traded in other countries:TRL.Germany,
DaVita HealthCare Partners Inc operates kidney dialysis centers and provides related lab services mainly in dialysis centers and in contracted hospitals across the United States. It also operates other ancillary services and strategic initiatives.

DaVita Inc, formerly DaVita HealthCare Partners Inc was incorporated as a Delaware corporation in 1994. It is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD. The Company also provides administrative and management support services to a medical services joint venture in which the Company owns a 50% interests. As of December 31, 2014, it provided dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 173,000 patients. It also provides acute inpatient dialysis services in approximately 1,000 hospitals and related laboratory services throughout the United States. The United States dialysis and related lab services business. Home-based dialysis services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance to patients who prefer and are able to receive either peritoneal dialysis or hemodialysis treatments in their homes. It provides hospital inpatient hemodialysis services are required for patients with acute kidney failure resulting from trauma, patients in early stages of ESRD and ESRD patients who require hospitalization for other reasons. It owns two separately incorporated, licensed, clinical laboratories, both located in Florida, specializing in ESRD patient testing. These specialized laboratories provide routine laboratory tests covered by the Medicare composite payment rate for dialysis and other physician-prescribed laboratory tests for ESRD patients. The Company's laboratories provide these tests predominantly for its own ESRD patients throughout the United States. It currently operates or provides management and administrative services to 29 outpatient dialysis centers, in which it either owns a non-controlling interest, or is wholly-owned by third parties, under management and administrative services agreements. It continues to face increased competition in the dialysis industry from large and medium-sized providers which compete directly with it for acquisition targets as well as for individual patients.

Top Ranked Articles about DaVita Inc

Another Attempt to Trumpet a Misjudgment Reflections on mistakes made in another investment analysis
Arnold Van Den Berg Sells Coca-Cola, DaVita Largest trades by the investor in the second quarter
Arnold Van Den Berg (Trades, Portfolio) is a value investor and considers himself a student of Benjamin Graham. His investment research seeks to determine the appraised value of a company, often referred to as intrinsic value. Read more...
Low P/S Ratios for DaVita, ConAgra Foods Gurus have been snapping up these stocks
According to GuruFocus' All-in-One Screener, the following are companies with market caps above $5 billion that are trading with low P/S ratios. Read more...
Weekly CEO Sells Highlights Insiders sell INC Research Holdings, DaVita HealthCare Partners, TE Connectivity, Ruckus Wireless
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: INC Research Holdings Inc. (NASDAQ:INCR), DaVita HealthCare Partners Inc. (NYSE:DVA), TE Connectivity Ltd. (NYSE:TEL) and Ruckus Wireless Inc. (NYSE:RKUS). Read more...
Steve Mandel Sells Health Care Stakes Guru sells holdings in Allergan and DaVita HealthCare Partners
Steve Mandel (Trades, Portfolio), founder of Lone Pine Capital, sold out two health care stakes in the fourth quarter. Read more...

Ratios

vs
industry
vs
history
PE Ratio 16.06
DVA's PE Ratio is ranked higher than
80% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 25.24 vs. DVA: 16.06 )
Ranked among companies with meaningful PE Ratio only.
DVA' s PE Ratio Range Over the Past 10 Years
Min: 11.6  Med: 18.74 Max: 58.72
Current: 16.06
11.6
58.72
Forward PE Ratio 18.87
DVA's Forward PE Ratio is ranked higher than
61% of the 76 Companies
in the Global Medical Care industry.

( Industry Median: 20.20 vs. DVA: 18.87 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 16.06
DVA's PE Ratio without NRI is ranked higher than
82% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 26.44 vs. DVA: 16.06 )
Ranked among companies with meaningful PE Ratio without NRI only.
DVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.57  Med: 18.73 Max: 58.72
Current: 16.06
11.57
58.72
Price-to-Owner-Earnings 10.70
DVA's Price-to-Owner-Earnings is ranked higher than
85% of the 93 Companies
in the Global Medical Care industry.

( Industry Median: 27.99 vs. DVA: 10.70 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DVA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.66  Med: 16.69 Max: 674.95
Current: 10.7
9.66
674.95
PB Ratio 2.87
DVA's PB Ratio is ranked lower than
51% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 2.73 vs. DVA: 2.87 )
Ranked among companies with meaningful PB Ratio only.
DVA' s PB Ratio Range Over the Past 10 Years
Min: 2.25  Med: 3.23 Max: 6.46
Current: 2.87
2.25
6.46
PS Ratio 0.96
DVA's PS Ratio is ranked higher than
72% of the 256 Companies
in the Global Medical Care industry.

( Industry Median: 1.67 vs. DVA: 0.96 )
Ranked among companies with meaningful PS Ratio only.
DVA' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 1.17 Max: 1.77
Current: 0.96
0.77
1.77
Price-to-Free-Cash-Flow 12.50
DVA's Price-to-Free-Cash-Flow is ranked higher than
82% of the 115 Companies
in the Global Medical Care industry.

( Industry Median: 23.76 vs. DVA: 12.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.52  Med: 16.16 Max: 42.52
Current: 12.5
7.52
42.52
Price-to-Operating-Cash-Flow 7.20
DVA's Price-to-Operating-Cash-Flow is ranked higher than
85% of the 168 Companies
in the Global Medical Care industry.

( Industry Median: 14.75 vs. DVA: 7.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.22  Med: 9.21 Max: 17.87
Current: 7.2
5.22
17.87
EV-to-EBIT 11.30
DVA's EV-to-EBIT is ranked higher than
88% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 20.76 vs. DVA: 11.30 )
Ranked among companies with meaningful EV-to-EBIT only.
DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 12.1 Max: 20.4
Current: 11.3
8.5
20.4
EV-to-EBITDA 8.22
DVA's EV-to-EBITDA is ranked higher than
88% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 15.90 vs. DVA: 8.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 9.6 Max: 15.4
Current: 8.22
6.8
15.4
PEG Ratio 1.94
DVA's PEG Ratio is ranked higher than
66% of the 79 Companies
in the Global Medical Care industry.

( Industry Median: 2.80 vs. DVA: 1.94 )
Ranked among companies with meaningful PEG Ratio only.
DVA' s PEG Ratio Range Over the Past 10 Years
Min: 0.41  Med: 1.47 Max: 5.58
Current: 1.94
0.41
5.58
Shiller PE Ratio 26.51
DVA's Shiller PE Ratio is ranked higher than
60% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 29.68 vs. DVA: 26.51 )
Ranked among companies with meaningful Shiller PE Ratio only.
DVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.65  Med: 29.5 Max: 50.42
Current: 26.51
19.65
50.42
Current Ratio 1.48
DVA's Current Ratio is ranked higher than
58% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.29 vs. DVA: 1.48 )
Ranked among companies with meaningful Current Ratio only.
DVA' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.78 Max: 3.17
Current: 1.48
0.39
3.17
Quick Ratio 1.41
DVA's Quick Ratio is ranked higher than
59% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.15 vs. DVA: 1.41 )
Ranked among companies with meaningful Quick Ratio only.
DVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.71 Max: 3.04
Current: 1.41
0.37
3.04
Days Inventory 6.45
DVA's Days Inventory is ranked higher than
78% of the 186 Companies
in the Global Medical Care industry.

( Industry Median: 16.39 vs. DVA: 6.45 )
Ranked among companies with meaningful Days Inventory only.
DVA' s Days Inventory Range Over the Past 10 Years
Min: 3.72  Med: 6 Max: 8.61
Current: 6.45
3.72
8.61
Days Sales Outstanding 47.46
DVA's Days Sales Outstanding is ranked lower than
55% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 42.10 vs. DVA: 47.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.53  Med: 62.54 Max: 69.35
Current: 47.46
43.53
69.35
Days Payable 17.91
DVA's Days Payable is ranked lower than
77% of the 157 Companies
in the Global Medical Care industry.

( Industry Median: 39.14 vs. DVA: 17.91 )
Ranked among companies with meaningful Days Payable only.
DVA' s Days Payable Range Over the Past 10 Years
Min: 14.92  Med: 19.24 Max: 27.07
Current: 17.91
14.92
27.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
DVA's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 121 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. DVA: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.6  Med: -0.6 Max: 9.3
Current: 3
-22.6
9.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.81
DVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
87% of the 99 Companies
in the Global Medical Care industry.

( Industry Median: 1.79 vs. DVA: 0.81 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.12 Max: 2.55
Current: 0.81
0.75
2.55
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.34
DVA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
77% of the 30 Companies
in the Global Medical Care industry.

( Industry Median: 1.76 vs. DVA: 1.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.82
DVA's Price-to-Median-PS-Value is ranked higher than
77% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 1.03 vs. DVA: 0.82 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 1 Max: 1.82
Current: 0.82
0.34
1.82
Price-to-Peter-Lynch-Fair-Value 2.29
DVA's Price-to-Peter-Lynch-Fair-Value is ranked higher than
50% of the 44 Companies
in the Global Medical Care industry.

( Industry Median: 2.22 vs. DVA: 2.29 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
DVA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.31 Max: 8.16
Current: 2.29
0.56
8.16
Earnings Yield (Greenblatt) % 8.82
DVA's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. DVA: 8.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.9  Med: 8.3 Max: 11.8
Current: 8.82
4.9
11.8
Forward Rate of Return (Yacktman) % 12.95
DVA's Forward Rate of Return (Yacktman) % is ranked higher than
63% of the 112 Companies
in the Global Medical Care industry.

( Industry Median: 9.73 vs. DVA: 12.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 12.3  Med: 20.6 Max: 35.1
Current: 12.95
12.3
35.1

More Statistics

Revenue (TTM) (Mil) $14,745
EPS (TTM) $ 4.29
Beta1.04
Short Percentage of Float3.50%
52-Week Range $54.50 - 78.77
Shares Outstanding (Mil)194.55

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 15,279 16,231
EPS ($) 3.85 3.93
EPS without NRI ($) 3.85 3.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.34%
Dividends per Share ($)
» More Articles for DVA

Headlines

Articles On GuruFocus.com
Another Attempt to Trumpet a Mistake Dec 19 2016 
Are Any of Buffett's Holdings Cheap Enough to Buy? Nov 09 2016 
3 Warren Buffett Stocks Fall to 52-Week Lows Oct 28 2016 
Baxter Well Positioned in Fast-Growing Market for Kidney Dialysis Equipment Jul 01 2016 
Arnold Van Den Berg's Largest Buys in 1st Quarter Apr 21 2016 
Weekly CEO Sells Highlights Apr 18 2016 
7 High Quality Guru Stocks Apr 11 2016 
Steve Mandel Sells Health Care Stakes Mar 11 2016 
Undervalued, Predictable Companies Include Monsanto and Western Union Mar 10 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 

More From Other Websites
DaVita Appoints Chief Medical Officer for Integrated Kidney Care Feb 23 2017
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against DaVita... Feb 22 2017
DaVita sued over claims it pushed clients into unnecessary insurance plans Feb 22 2017
DaVita, Inc. :DVA-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017 Feb 22 2017
DVA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Feb 22 2017
Cigna Ties Up with DaVita Unit for New Healthcare Plans Feb 22 2017
DaVita (DVA) Ties Up with Cigna Arm, Expands in Los Angeles Feb 22 2017
DaVita is targeted by California bill to increase its staffing levels at clinics Feb 21 2017
Cigna and HealthCare Partners Form Alliance to Deliver Innovative Health Plans in Los Angeles Feb 21 2017
Finding the Bullish and Bearish Reversals Feb 21 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Feb 21 2017
Important Deadline for DaVita Inc. Shareholders Feb 21 2017
DaVita, Inc. :DVA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017 Feb 21 2017
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against DaVita... Feb 17 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of DaVita Inc. of a Class Action... Feb 17 2017
DaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4 Feb 17 2017
Edited Transcript of DVA earnings conference call or presentation 16-Feb-17 10:00pm GMT Feb 17 2017
DaVita Shares Rise on Positive Earnings Feb 16 2017
After successful 2016, DaVita predicts income drop in 2017 Feb 16 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against DaVita... Feb 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)